share_log

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34

Wedbush維持對Kiniksa Pharmaceuticals的跑贏大盤評級,並將其目標股價上調至34美元。
Benzinga ·  07/23 12:55  · 評級/大行評級

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $30 to $34.

Wedbush分析師戴維·尼倫加滕維持Kiniksa Pharmicals(納斯達克股票代碼:KNSA)的跑贏大盤,並將目標股價從30美元上調至34美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論